D-0032-2026 Class III Ongoing

Recalled by JB Chemicals And Pharmaceuticals Ltd — Mumbai

FDA drug recall D-0032-2026 was initiated by JB Chemicals And Pharmaceuticals Ltd on Sep 12, 2025 and is designated Class III. Reason for recall: Tablet/Capsules Imprinted with Wrong ID The recall status is ongoing. Affected quantity: 9936 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 29, 2025
Initiation Date
Sep 12, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
9936 bottles

Product description

Cetirizine Hydrochloride Tablets USP 10 mg, 100 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-402-10.

Reason for recall

Tablet/Capsules Imprinted with Wrong ID

Distribution pattern

U.S. Nationwide

Code information

Lot # PY925014A; Exp. 1/31/2028

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0032-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0032-2026. Report a data issue: hello@regdatalab.com.